ABSTRACT: The aim of the present study was to investigate the presence of anti-fibroblast antibodies in patients with idiopathic or scleroderma-associated pulmonary arterial hypertension (PAH) and healthy controls.
P ulmonary arterial hypertension (PAH) is a rare clinical condition leading to progressive right-heart failure and death [1] . PAH is defined by a mean pulmonary artery pressure .25 mmHg at rest or .30 mmHg with exercise in the absence of a post-capillary process as assessed by right-heart catheterisation [2] . PAH occurs as a consequence of chronic obstruction of small pulmonary arteries secondary to dysfunctions and proliferation of endothelial cells, vascular smooth muscle cells and fibroblasts [3] .
According to the World Health Organization classification established in Venice in 2003 [4] , PAH is classified as idiopathic (IPAH), familial or related to other conditions: dexfenfluramine therapy [1] , HIV infection [5] , portal hypertension, congenital heart disease, and connective tissue diseases such as systemic sclerosis (SSc). Thus, ,10-14% of SSc patients develop PAH [6] , which is responsible for a high mortality rate.
The formation of a layer of myofibroblasts and extracellular matrix between the endothelium and the internal elastic lamina, termed neointima, is a hallmark of severe PAH. In hypoxia models, adventitial fibroblasts appear to be first cells activated to proliferate and to synthesise matrix proteins in response to pulmonary hypertensive stimulus [7] .
To date, very few studies have been conducted to identify autoantibodies in the serum of PAH patients. A recent study identified anti-endothelial cell immunoglobulin (Ig)G antibodies in patients with IPAH or SSc-associated PAH [8] . Since fibroblast dysfunctions have been identified in both SSc and IPAH, and since anti-fibroblast antibodies that are able to activate and induce collagen synthesis have been detected in the serum of SSc patients [9] , the current authors analysed the reactivity profiles of anti-fibroblast antibodies in patients with IPAH or SSc-associated PAH and in healthy individuals. This work has been presented at the 5th annual congress of the European Lung Against Rheumatism (EULAR) on June 9-11, 2004 in Berlin, Germany.
MATERIALS AND METHODS

Patients
All patients gave their written informed consent according to the ethics committee of the La Pitié-Salpêtrière Hospital Group (Paris, France). PAH was detected as systolic pulmonary artery pressure .40 mmHg upon echocardiography, and confirmed by right-heart catheterisation as mean pulmonary artery pressure at rest .25 mmHg. By convention, PAH patients were labelled as having IPAH if they displayed PAH with no evidence of an associated disease (corresponding to sporadic, familial and fenfluramine-associated PAH). SSc patients fulfilled the LEROY and MEDSGER [10] and/or the American Rheumatism Association [11] 
Cell culture
Normal human dermal fibroblasts were cultured from normal skin. Biopsy specimens were cut and seeded into Petri dishes and cultured as previously described [9] . Human epithelial (HEp)-2 cells were obtained and cultured as previously reported [8] .
ELISA detection of anti-fibroblast antibodies A cell-based ELISA was performed on fixed and unpermeabilised fibroblasts [12] . In order to adjust for interassay variability, the optical density value of a positive reference serum was arbitrarily defined as 100% of anti-fibroblast activity. The results of tested samples were expressed as a percentage of this positive reference value. All samples were tested in duplicate.
Immunoblotting detection of anti-fibroblast and anti-HEp-2 cell antibodies Antibody reactivities were analysed using a semiquantitative immunoblotting technique with normal human fibroblasts and HEp-2 cells. ANTIBODIES TO FIBROBLASTS M.C. TAMBY ET AL.
using a semi-dry electroblotter (model A; Ancos, Hojby, Denmark). After blocking with PBS-0.2% Tween for 90 min, the membranes were incubated with sera for 4 h at room temperature, at 100 mg?mL -1 IgG or 20 mg?mL -1 IgM in a Cassette Miniblot System (Immunetics Inc., Cambridge, MA, USA). They were then extensively washed before being incubated with either secondary rabbit anti-human crystallisable fragment (Fc)-c or Fc-m antibody coupled to alkaline phosphatase (Dako, Glostrup, Denmark) for 90 min at room temperature. Immunoreactivities were revealed using the nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl-phosphate substrate (Sigma-Aldrich, St Louis, MO, USA). Immunoreactivities were quantified by scanning the membranes with a densitometer (Epson Perfection 1200S; Seiko Epson Corporation, Nagano-Ken, Japan). The membranes were then stained with colloidal gold (Protogold1; Biocell, Cardiff, UK) and subjected to a second densitometric analysis to quantify transferred proteins. This approach allows the immunoreactivity repertoires to be compared by referring to their respective protein peaks corrected for electrophoretic migration defects by superimposing corresponding protein peaks using computer analysis. Standard IgG or IgM preparations, included in each blot, allow rescaling of the membranes transferred with a given protein extract and adjustment for the intensity of labelling on different membranes [13, 14] .
Statistical analyses
For the analysis of ELISA data, the mean relative optical densities of two groups were compared using the t-test. Immunoblotting data were submitted to multivariate statistical analysis because of the large number of reactivities revealed. Therefore, IGOR software (Igor Pro 3.16, Wavemetrics Inc, Lake Oswego, OR, USA) with specially designed packages and Systat software (version 11.0, Systat Software Inc., Point Richmond, CA, USA), were used. Densitometry curves of the IgG and IgM reactivities of each patient and controls on each of the different protein extracts were divided into sections surrounding individual peaks of immunoreactivity on each substrate. Eight to ten sections were selected, depending on the protein extract used and number of antibody reactivities identified in the blots. The number of comparisons performed was limited on a basis of clinical relevance, and five comparisons were performed for IgG and for IgM reactivities: all PAH patients versus healthy controls; IPAH patients versus healthy controls; SSc-PAH patients versus healthy controls; IPAH patients versus SSc-PAH patients; and SSc-PAH patients versus SSc patients without PAH . In order to compare groups of individuals (groups of patients two by two and patients and controls), for each comparison, the factor scores of each of the subjects were calculated after performing factor analysis of the whole data [8, 15] . Factor scores were submitted either to a paired Wilcoxon test to compare repertoires of reactivities of patients to age-and sex-matched healthy controls, or to a Mann-Whitney U-test to compare repertoires of reactivities of patients two by two. The number and the molecular weights of contributing protein bands varied according to the source of antigens tested and the two groups compared [8, 13] .
RESULTS
ELISA detection of anti-fibroblast IgG antibodies
The serum IgG reactivities to fibroblasts of IPAH patients, SSc patients with or without PAH and healthy controls were tested using a cell-based ELISA. Using a threshold defined by two standard deviations over the mean optical density of IgG reactivities of healthy individuals, 14 out of 35 (40%) IPAH patients, three out of 10 (30%) SSc-PAH patients, one out of 10 (10%) limited cutaneous SSc without PAH patients, three out of 10 (30%) diffuse SSc without PAH patients and two out of 65 (3.1%) healthy individuals had anti-fibroblast antibodies ( fig. 1 ). When the threshold was moved to three standard deviations over the mean optical density of healthy controls, 10 out of 35 (28.6%) IPAH patients, three out of 10 (30%) SSc-PAH patients, one out of 10 (10%) limited cutaneous SSc without PAH patients, two out of 10 (20%) diffuse SSc without PAH patients but none of the healthy controls had anti-fibroblast antibodies ( fig. 1) . The mean IgG anti-fibroblast antibody serum levels of patients with IPAH, SSc-PAH patients and diffuse SSc without PAH patients were significantly higher than those of healthy individuals ( fig. 1 ), whereas the mean IgG anti-fibroblast antibody serum levels of limited cutaneous SSc patients without PAH were not. No significant differences were observed between the mean serum levels of IgG antifibroblast antibodies of the different groups of patients.
Immunoblot detection of anti-fibroblast IgG reactivities Serum IgG reactivity patterns were homogeneous among healthy individuals and patients within each group. However, IgG antibodies from a few healthy individuals and patients in each group bound to unique bands with high intensity. IgG from all patients and healthy individuals bound to one major protein band of 40 kDa (figs 2 and 3). IgG from IPAH patients bound to two 25-and 60-kDa bands with a higher intensity than IgG from other individuals. In addition, IgG antibodies from healthy controls and all patients except 
Detection of anti-fibroblast IgM reactivities
The serum IgM reactivities to fibroblasts of patients with IPAH and SSc-PAH, and SSc without PAH, as well as healthy controls, were tested using cell-based ELISA. Using a threshold defined by two standard deviations over the mean optical density of IgM reactivities of healthy individuals, none of the patients and healthy controls expressed anti-fibroblast antibodies (data not shown).
When tested by immunoblotting, serum IgM reactivity patterns were homogeneous among healthy individuals and patients in each group. IgM antibodies from a few healthy individuals and patients in each group bound to unique bands with high intensity. IgM from all patients and healthy individuals bound to one major protein band of 40 kDa ( did not differ significantly between IPAH and SSc-PAH patients or between SSc-PAH patients and SSc patients without PAH (table 4) .
DISCUSSION
The present study has demonstrated for the first time that IgG and IgM anti-fibroblast antibodies are present in the serum of patients with PAH, with distinct reactivity patterns in IPAH and SSc-associated PAH.
It is well established that SSc patients express anti-fibroblast antibodies [9, 16, 17] . In the current study, anti-fibroblast antibodies have been evidenced in 25% of SSc patients without PAH and in 30% of SSc patients with PAH, whereas CHIZZOLINI et al. [9] detected anti-fibroblast antibodies in 58% of SSc patients using cell-based ELISA. In SSc patients, anti-fibroblast antibodies have previously been shown to induce fibroblast activation in vitro and a pro-adhesive and pro-inflammatory phenotype of these cells [9] . Thus, IgG binding to the surface of fibroblasts could induce autocrine production of cytokines such as interleukin-1a, interleukin-1b and interleukin-6, which in turn could upregulate the expression of intercellular adhesion molecule (ICAM)-1 on the fibroblast surface [9] . Very few studies have been published regarding the specificity of anti-fibroblast antibodies. In SSc, DNA topoisomerase 1 was recently identified as the target of anti-fibroblast antibodies, with evidence that anti-topoisomerase 1 antibodies display anti-fibroblast activity by reacting with determinants at the fibroblast surface [17] .
To the current authors' knowledge, anti-fibroblast antibodies have not previously been detected in the serum of patients with IPAH. PAH pathophysiology relies classically on an imbalance of intimal vasoconstrictors and vasodilators, decreased expression of potassium channels, adventitial increased expression of tenascin, inflammation, misguided angiogenesis and hypercoagulability [18] . Genetic susceptibility is important in PAH, since mutations in the type 2 transforming growth factor (TGF)-b receptor gene are present in ,30% of plexiform lesions [19] . Germ-line mutations of bone morphogenic protein receptor (BMPR)-II, a member of the TGF-b receptor family, are well documented in familial, idiopathic and fenfluramine-associated PAH. Interestingly, no mutation of the gene coding for BMPR-II has been identified in SSc patients with PAH [20] .
There is some evidence suggesting a role for an auto-immune process in PAH [21] . Indeed, PAH is a common complication of autoimmune diseases such as SSc, mixed connective tissue disease and systemic lupus erythematosus [4] . Pulmonary arterial lesions in the lungs of patients suffering from PAH associated with connective tissue diseases are similar to those found in IPAH [3] . This resemblance in pathological anatomy may suggest similar mechanisms. Besides medial hypertrophy, intimal ''onion bulb'' lesions and characteristic glomoid-like plexiform lesions, COOL et al. [22] have reported that in patients with SSc-related PAH, mononuclear inflammatory cells surround vascular sites of plexiform growth, but not uninvolved vessels or extravascular lung structure. In in vitro experiments, auto-antibodies from patients with connective tissue diseases, including anti-U1-ribonucleoprotein antibodies and anti-double-stranded DNA antibodies, induced up-regulation of the expression of ICAM-1, endothelium leukocyte adhesion molecule 1 and major histocompatibility complex class II molecules on the surface of human pulmonary endothelial cells, suggesting that such an inflammatory process could lead to proliferative and inflammatory pulmonary vasculopathy [23] .
By contrast, less data are available regarding the detection of auto-antibodies in other subgroups of PAH patients. Nevertheless, in a significant proportion of IPAH patients there is evidence of auto-immunity and/or active inflammation, including detection of circulating autoantibodies [8, 24] , elevated serum levels of the pro-inflammatory cytokines interleukin (IL)-1 and IL-6, and increased pulmonary expression of platelet-derived growth factor or chemokines [3] . Some studies suggest a close association of IPAH and auto-immune thyroid disease, further supporting the possibility of an autoimmune mechanism in PAH [25] . In the present study, anti-fibroblast antibodies identified in the serum of IPAH patients were shown to express a major reactivity with a 60-kDa protein band, whereas IgG reactivities directed toward 70-, 75-and 95-kDa bands were specific to SSc patients, since none of those are shared with IgG from idiopathic PAH patients. The absence of IgG immunoreactivity with a 60-kDa band in HEp-2 cell extracts suggests the fibroblast specificity of IgG anti-fibroblast antibodies in IPAH patients. However, the current authors have previously reported that IgG from the same IPAH patients also bound to a 60-kDa protein in macrovascular endothelial cells, although this 60-kDa band was not present when sera were tested with microvascular lung and dermal endothelial cells [8] . Moreover, the present experiments were performed at an IgG concentration of 100 mg?mL -1 , whereas previous experiments regarding antiendothelial cell antibodies in IPAH patients were performed at an IgG concentration of 200 mg?mL -1 . Finally, the current authors have failed to show any significant difference between antibody reactivities from IPAH patients and from SSc patients with PAH, as well as between SSc patients with PAH and healthy controls. This absence of significant differences might be the consequence of the small number of SSc patients tested.
The target antigens of anti-fibroblast antibodies in PAH have not yet been identified. It is possible to speculate, since IgG anti-fibroblast antibodies bind to unpermeabilised fibroblasts as assessed by ELISA, that the target antigen(s) might be part of the fibroblast membrane. Whether these anti-fibroblast IgG antibodies arise as a consequence of overexpression of cellsurface antigens in the context of increased fibroblast proliferation, or from primary auto-immune reaction, is a matter of speculation. An attractive hypothesis would be to link these anti-fibroblast antibodies with structural abnormalities of cellsurface receptors that might result from genetic abnormalities i.e. of TGF-b receptor superfamily genes. The target antigens of IgG and IgM anti-fibroblast antibodies need to be characterised, as does their potential pathogenic role. Thus, irrespective of their exact target antigen, it is speculated that these auto-antibodies may induce an activating signal leading to cell proliferation and the release of mediators including cytokines, chemokines and growth factors which could contribute to the development of PAH [3] .
For the first time, the current authors provide evidence that patients with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with systemic sclerosis express anti-fibroblast antibodies. The target antigens and the potential pathogenic role of those antibodies remain to be determined [16] . The predictive value of these antibodies in patients at risk of developing pulmonary arterial hypertension, such as systemic sclerosis patients and patients with a familial history of pulmonary arterial hypertension, needs to be investigated.
